- Home
- APLS vs MIRM Comparison
APLS vs MIRM Comparison
Compare APLS & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLS
- MIRM
- Stock Information
- Founded
- APLS 2009
- MIRM 2018
- Country
- APLS United States
- MIRM United States
- Employees
- APLS N/A
- MIRM N/A
- Industry
- APLS Biotechnology: Pharmaceutical Preparations
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- APLS Health Care
- MIRM Health Care
- Exchange
- APLS Nasdaq
- MIRM Nasdaq
- Market Cap
- APLS 3.5B
- MIRM 3.3B
- IPO Year
- APLS 2017
- MIRM 2019
- Fundamental
- Price
- APLS $23.80
- MIRM $72.95
- Analyst Decision
- APLS Buy
- MIRM Strong Buy
- Analyst Count
- APLS 20
- MIRM 11
- Target Price
- APLS $33.47
- MIRM $76.09
- AVG Volume (30 Days)
- APLS 2.3M
- MIRM 732.9K
- Earning Date
- APLS 11-04-2025
- MIRM 11-11-2025
- Dividend Yield
- APLS N/A
- MIRM N/A
- EPS Growth
- APLS N/A
- MIRM N/A
- EPS
- APLS N/A
- MIRM N/A
- Revenue
- APLS $754,649,000.00
- MIRM $429,161,000.00
- Revenue This Year
- APLS $22.11
- MIRM $53.08
- Revenue Next Year
- APLS N/A
- MIRM $20.45
- P/E Ratio
- APLS N/A
- MIRM N/A
- Revenue Growth
- APLS 20.02
- MIRM 62.33
- 52 Week Low
- APLS $16.10
- MIRM $36.88
- 52 Week High
- APLS $35.72
- MIRM $78.10
- Technical
- Relative Strength Index (RSI)
- APLS 47.98
- MIRM 53.18
- Support Level
- APLS $21.07
- MIRM $70.49
- Resistance Level
- APLS $23.50
- MIRM $76.56
- Average True Range (ATR)
- APLS 0.80
- MIRM 2.09
- MACD
- APLS -0.03
- MIRM -0.72
- Stochastic Oscillator
- APLS 78.45
- MIRM 40.54
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.